Avenue Therapeutics, Inc.
Avenue Therapeutics, Inc. (ATXI) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ATXI · as of Jun 30, 2023
Ownership Breakdown
1
Institutional Holders
$29,000
Total Inst. Value
▼ $17,591 vs Q1
3.29M
Shares Outstanding
freeFloat 86.49%
25,000
13F Shares Held
▼ 14,992 vs Q1
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ATXI largest shareholders · institutional ownership
Q2 2023 · SEC 13F
Showing top 2 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
SHIKIAR ASSET MANAGEMENT INC pharmaceutical preparations | 25.0K | 1.12% | 1.12% | $29.00M | Jul 20, 2023 | NEW |
ICON WEALTH PARTNERS, LLC pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Aug 3, 2023 | EXIT |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q2 2023 vs prior quarter
Q2 2023
0
Increased
+0 shares1
New Positions
first time holders0
Decreased
−0 shares1
Sold Out
fully exitedNet shares change (top 50)
+0
+0 / −0
Net new holders
+0
1 new / 1 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ATXI insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
1
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Fortress Biotech, Inc. 10 percent owner | Jan 2, 2026 | Award | 111,209 | — | — | 439.7K | Form 4 ↗ |
Fortress Biotech, Inc. 10 percent owner | Mar 31, 2025 | Award | 33,724 | — | — | 328.5K | Form 4 ↗ |
Herskowitz Neil director | Dec 2, 2024 | Sale | 23 | $2.00 | $46 | 97 | Form 4 ↗ |
KRANZLER JAY D director | Nov 5, 2024 | Sale | 61 | $2.24 | $136.64 | 559 | Form 4 ↗ |
KRANZLER JAY D director | Sep 30, 2024 | Purchase | 497 | $2.50 | $1.2K | 620 | Form 4 ↗ |
KRANZLER JAY D director | Sep 27, 2024 | Purchase | 3 | $2.40 | $7.2 | 123 | Form 4 ↗ |
ROSENWALD LINDSAY A MD director | Sep 23, 2024 | Award | 30,000 | $2.46 | $73.8K | 30.0K | Form 4 ↗ |
Herskowitz Neil director | Sep 23, 2024 | Award | 30,000 | $2.46 | $73.8K | 30.0K | Form 4 ↗ |
Oltmans Curtis Gale director | Sep 23, 2024 | Award | 30,000 | $2.46 | $73.8K | 30.0K | Form 4 ↗ |
MacLean Alexandra Chief Executive Officer | Sep 23, 2024 | Award | 170,000 | — | — | 170.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Avenue Therapeutics, Inc. (ATXI) is primarily owned by institutional investors, who hold approximately 0.8% of total shares outstanding. Company insiders own approximately 13.51%, while retail and public investors account for the remaining 85.74%.
The largest institutional shareholder of Avenue Therapeutics, Inc. is SHIKIAR ASSET MANAGEMENT INC, holding approximately 25,000 shares — equal to 1.12% of outstanding shares — as of June 30, 2023.
A total of 1 institutional investors currently hold ATXI stock, with a combined institutional value of approximately $29,000 as of the most recent 13F filing period.
Frequently asked questions
ATXI ownershipAvenue Therapeutics, Inc. (ATXI) is primarily owned by institutional investors, who hold approximately 0.8% of shares. The largest shareholder is SHIKIAR ASSET MANAGEMENT INC with a 1.12% stake. Company insiders hold 13.51%. Data sourced from SEC Form 13F as of June 30, 2023.